DrugPatentWatch Database Preview
Drugs in Development Information for Navitoclax
» See Plans and Pricing
What is the drug development status for Navitoclax?
Navitoclax is an investigational drug.
There have been 19 clinical trials for Navitoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 14th 2020.
The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.
There are one hundred and seventy-six US patents protecting this investigational drug and two international patents.
Summary for Navitoclax
| US Patents | 176 |
| International Patents | 2,074 |
| US Patent Applications | 344 |
| WIPO Patent Applications | 1,244 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2020-09-14) |
| Vendors | 74 |
Recent Clinical Trials for Navitoclax
| Title | Sponsor | Phase |
|---|---|---|
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | AbbVie | Phase 3 |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | AbbVie | Phase 1 |
| Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis | AbbVie | Phase 3 |
Clinical Trial Summary for Navitoclax
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
US Patents for Navitoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Navitoclax | Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | Start Trial |
| Navitoclax | Start Trial | Antibody drug conjugates | Novartis AG (Basel, CH) | Start Trial |
| Navitoclax | Start Trial | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | Start Trial |
| Navitoclax | Start Trial | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | AbbVie Inc. (North Chicago, IL) | Start Trial |
| Navitoclax | Start Trial | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Navitoclax
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Navitoclax | Canada | CA2922341 | 2033-08-28 | Start Trial |
| Navitoclax | European Patent Office | EP3038618 | 2033-08-28 | Start Trial |
| Navitoclax | World Intellectual Property Organization (WIPO) | WO2015031608 | 2033-08-28 | Start Trial |
| Navitoclax | Argentina | AR102649 | 2034-11-14 | Start Trial |
| Navitoclax | Australia | AU2015347015 | 2034-11-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
